Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Emory University
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Mayo Clinic